NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

醫藥品有效成分/API的全球市場

Active Pharmaceutical Ingredients/API

出版商 Global Industry Analysts, Inc. 商品編碼 997398
出版日期 內容資訊 英文 220 Pages
商品交期: 最快1-2個工作天內
價格
醫藥品有效成分/API的全球市場 Active Pharmaceutical Ingredients/API
出版日期: 2021年04月01日內容資訊: 英文 220 Pages
簡介

全球醫藥品有效成分/API的市場規模,預計在分析期間(2020年∼2027年)將以4.9%的年複合成長率增長,從2020年的1,834億美元,到2027年達到2,557億美元。

本報告所分析的市場區隔之一的創新的醫藥品部門,在分析期間中預計將以4.7%的年複合成長率增長,達到1,009億美元。

本報告提供全球醫藥品有效成分/API市場的相關調查,提供市場佔有率,Covid-19的影響,趨勢和成長要素,各地區的市場分析,競爭情形,主要企業的簡介等資訊。

調查對象企業範例

  • AbbVie, Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Pfizer, Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.

目錄

I. 調查手法

II. 摘要整理

  • 市場概要
    • 影響者市場洞察
    • 全球市場的軌跡
    • Covid-19的影響與即將到來的全球景氣衰退
  • 主要企業
  • 趨勢與推動要素
  • 全球市場預測

III. 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲
  • 亞太地區
  • 其他地區

IV. 競爭

  • 企業簡介:46公司

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP10061

Abstract:

Global Active Pharmaceutical Ingredients/API Market to Reach $255.7 Billion by 2027

Amid the COVID-19 crisis, the global market for Active Pharmaceutical Ingredients/API estimated at US$183.4 Billion in the year 2020, is projected to reach a revised size of US$255.7 Billion by 2027, growing at aCAGR of 4.9% over the period 2020-2027. Innovative, one of the segments analyzed in the report, is projected to record 4.7% CAGR and reach US$100.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Generic segment is readjusted to a revised 5% CAGR for the next 7-year period.

The U.S. Market is Estimated at $54 Billion, While China is Forecast to Grow at 4.6% CAGR

The Active Pharmaceutical Ingredients/API market in the U.S. is estimated at US$54 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$45.2 Billion by the year 2027 trailing a CAGR of 4.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.6% and 3.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Select Competitors (Total 46 Featured) -

  • AbbVie, Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Pfizer, Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Active Pharmaceutical Ingredients: An Overview
    • Rapid Growth of Healthcare Industry Drives Demand for API
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Factors Influencing the Demand of Active Pharmaceutical Ingredients
    • Gene-Editing - New Techniques Emerging within the Biologics Industry
    • API-in-Capsule Fast-Tracking Drug Development Process
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Active Pharmaceutical Ingredients/API by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Active Pharmaceutical Ingredients/API by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Active Pharmaceutical Ingredients/API by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Innovative by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Innovative by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Innovative by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Generic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Generic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Generic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Captive by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Captive by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Captive by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Merchant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Merchant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Merchant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Synthetic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Synthetic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Synthetic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Biotech by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Biotech by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Biotech by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 22: USA Current & Future Analysis for Active Pharmaceutical Ingredients/API by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 23: USA Historic Review for Active Pharmaceutical Ingredients/API by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 24: USA 15-Year Perspective for Active Pharmaceutical Ingredients/API by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027
    • TABLE 25: USA Current & Future Analysis for Active Pharmaceutical Ingredients/API by Manufacturer - Captive and Merchant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 26: USA Historic Review for Active Pharmaceutical Ingredients/API by Manufacturer - Captive and Merchant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 27: USA 15-Year Perspective for Active Pharmaceutical Ingredients/API by Manufacturer - Percentage Breakdown of Value Sales for Captive and Merchant for the Years 2012, 2020 & 2027
    • TABLE 28: USA Current & Future Analysis for Active Pharmaceutical Ingredients/API by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 29: USA Historic Review for Active Pharmaceutical Ingredients/API by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 30: USA 15-Year Perspective for Active Pharmaceutical Ingredients/API by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 31: Canada Current & Future Analysis for Active Pharmaceutical Ingredients/API by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 32: Canada Historic Review for Active Pharmaceutical Ingredients/API by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 33: Canada 15-Year Perspective for Active Pharmaceutical Ingredients/API by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027
    • TABLE 34: Canada Current & Future Analysis for Active Pharmaceutical Ingredients/API by Manufacturer - Captive and Merchant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 35: Canada Historic Review for Active Pharmaceutical Ingredients/API by Manufacturer - Captive and Merchant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 36: Canada 15-Year Perspective for Active Pharmaceutical Ingredients/API by Manufacturer - Percentage Breakdown of Value Sales for Captive and Merchant for the Years 2012, 2020 & 2027
    • TABLE 37: Canada Current & Future Analysis for Active Pharmaceutical Ingredients/API by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 38: Canada Historic Review for Active Pharmaceutical Ingredients/API by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 39: Canada 15-Year Perspective for Active Pharmaceutical Ingredients/API by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 40: Japan Current & Future Analysis for Active Pharmaceutical Ingredients/API by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 41: Japan Historic Review for Active Pharmaceutical Ingredients/API by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: Japan 15-Year Perspective for Active Pharmaceutical Ingredients/API by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027
    • TABLE 43: Japan Current & Future Analysis for Active Pharmaceutical Ingredients/API by Manufacturer - Captive and Merchant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Japan Historic Review for Active Pharmaceutical Ingredients/API by Manufacturer - Captive and Merchant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 45: Japan 15-Year Perspective for Active Pharmaceutical Ingredients/API by Manufacturer - Percentage Breakdown of Value Sales for Captive and Merchant for the Years 2012, 2020 & 2027
    • TABLE 46: Japan Current & Future Analysis for Active Pharmaceutical Ingredients/API by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Japan Historic Review for Active Pharmaceutical Ingredients/API by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 48: Japan 15-Year Perspective for Active Pharmaceutical Ingredients/API by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 49: China Current & Future Analysis for Active Pharmaceutical Ingredients/API by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 50: China Historic Review for Active Pharmaceutical Ingredients/API by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 51: China 15-Year Perspective for Active Pharmaceutical Ingredients/API by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027
    • TABLE 52: China Current & Future Analysis for Active Pharmaceutical Ingredients/API by Manufacturer - Captive and Merchant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 53: China Historic Review for Active Pharmaceutical Ingredients/API by Manufacturer - Captive and Merchant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 54: China 15-Year Perspective for Active Pharmaceutical Ingredients/API by Manufacturer - Percentage Breakdown of Value Sales for Captive and Merchant for the Years 2012, 2020 & 2027
    • TABLE 55: China Current & Future Analysis for Active Pharmaceutical Ingredients/API by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: China Historic Review for Active Pharmaceutical Ingredients/API by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 57: China 15-Year Perspective for Active Pharmaceutical Ingredients/API by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2012, 2020 & 2027
  • EUROPE
    • API Supply Chain Overview
    • TABLE 58: Europe Current & Future Analysis for Active Pharmaceutical Ingredients/API by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 59: Europe Historic Review for Active Pharmaceutical Ingredients/API by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 60: Europe 15-Year Perspective for Active Pharmaceutical Ingredients/API by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 61: Europe Current & Future Analysis for Active Pharmaceutical Ingredients/API by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Europe Historic Review for Active Pharmaceutical Ingredients/API by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 63: Europe 15-Year Perspective for Active Pharmaceutical Ingredients/API by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027
    • TABLE 64: Europe Current & Future Analysis for Active Pharmaceutical Ingredients/API by Manufacturer - Captive and Merchant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Europe Historic Review for Active Pharmaceutical Ingredients/API by Manufacturer - Captive and Merchant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 66: Europe 15-Year Perspective for Active Pharmaceutical Ingredients/API by Manufacturer - Percentage Breakdown of Value Sales for Captive and Merchant for the Years 2012, 2020 & 2027
    • TABLE 67: Europe Current & Future Analysis for Active Pharmaceutical Ingredients/API by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Europe Historic Review for Active Pharmaceutical Ingredients/API by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 69: Europe 15-Year Perspective for Active Pharmaceutical Ingredients/API by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 70: France Current & Future Analysis for Active Pharmaceutical Ingredients/API by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 71: France Historic Review for Active Pharmaceutical Ingredients/API by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 72: France 15-Year Perspective for Active Pharmaceutical Ingredients/API by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027
    • TABLE 73: France Current & Future Analysis for Active Pharmaceutical Ingredients/API by Manufacturer - Captive and Merchant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 74: France Historic Review for Active Pharmaceutical Ingredients/API by Manufacturer - Captive and Merchant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 75: France 15-Year Perspective for Active Pharmaceutical Ingredients/API by Manufacturer - Percentage Breakdown of Value Sales for Captive and Merchant for the Years 2012, 2020 & 2027
    • TABLE 76: France Current & Future Analysis for Active Pharmaceutical Ingredients/API by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 77: France Historic Review for Active Pharmaceutical Ingredients/API by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 78: France 15-Year Perspective for Active Pharmaceutical Ingredients/API by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 79: Germany Current & Future Analysis for Active Pharmaceutical Ingredients/API by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Germany Historic Review for Active Pharmaceutical Ingredients/API by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 81: Germany 15-Year Perspective for Active Pharmaceutical Ingredients/API by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027
    • TABLE 82: Germany Current & Future Analysis for Active Pharmaceutical Ingredients/API by Manufacturer - Captive and Merchant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Germany Historic Review for Active Pharmaceutical Ingredients/API by Manufacturer - Captive and Merchant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 84: Germany 15-Year Perspective for Active Pharmaceutical Ingredients/API by Manufacturer - Percentage Breakdown of Value Sales for Captive and Merchant for the Years 2012, 2020 & 2027
    • TABLE 85: Germany Current & Future Analysis for Active Pharmaceutical Ingredients/API by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Germany Historic Review for Active Pharmaceutical Ingredients/API by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 87: Germany 15-Year Perspective for Active Pharmaceutical Ingredients/API by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 88: Italy Current & Future Analysis for Active Pharmaceutical Ingredients/API by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Italy Historic Review for Active Pharmaceutical Ingredients/API by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 90: Italy 15-Year Perspective for Active Pharmaceutical Ingredients/API by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027
    • TABLE 91: Italy Current & Future Analysis for Active Pharmaceutical Ingredients/API by Manufacturer - Captive and Merchant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Italy Historic Review for Active Pharmaceutical Ingredients/API by Manufacturer - Captive and Merchant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 93: Italy 15-Year Perspective for Active Pharmaceutical Ingredients/API by Manufacturer - Percentage Breakdown of Value Sales for Captive and Merchant for the Years 2012, 2020 & 2027
    • TABLE 94: Italy Current & Future Analysis for Active Pharmaceutical Ingredients/API by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Italy Historic Review for Active Pharmaceutical Ingredients/API by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 96: Italy 15-Year Perspective for Active Pharmaceutical Ingredients/API by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 97: UK Current & Future Analysis for Active Pharmaceutical Ingredients/API by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 98: UK Historic Review for Active Pharmaceutical Ingredients/API by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 99: UK 15-Year Perspective for Active Pharmaceutical Ingredients/API by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027
    • TABLE 100: UK Current & Future Analysis for Active Pharmaceutical Ingredients/API by Manufacturer - Captive and Merchant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 101: UK Historic Review for Active Pharmaceutical Ingredients/API by Manufacturer - Captive and Merchant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 102: UK 15-Year Perspective for Active Pharmaceutical Ingredients/API by Manufacturer - Percentage Breakdown of Value Sales for Captive and Merchant for the Years 2012, 2020 & 2027
    • TABLE 103: UK Current & Future Analysis for Active Pharmaceutical Ingredients/API by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 104: UK Historic Review for Active Pharmaceutical Ingredients/API by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 105: UK 15-Year Perspective for Active Pharmaceutical Ingredients/API by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 106: Rest of Europe Current & Future Analysis for Active Pharmaceutical Ingredients/API by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Rest of Europe Historic Review for Active Pharmaceutical Ingredients/API by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 108: Rest of Europe 15-Year Perspective for Active Pharmaceutical Ingredients/API by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027
    • TABLE 109: Rest of Europe Current & Future Analysis for Active Pharmaceutical Ingredients/API by Manufacturer - Captive and Merchant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 110: Rest of Europe Historic Review for Active Pharmaceutical Ingredients/API by Manufacturer - Captive and Merchant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 111: Rest of Europe 15-Year Perspective for Active Pharmaceutical Ingredients/API by Manufacturer - Percentage Breakdown of Value Sales for Captive and Merchant for the Years 2012, 2020 & 2027
    • TABLE 112: Rest of Europe Current & Future Analysis for Active Pharmaceutical Ingredients/API by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 113: Rest of Europe Historic Review for Active Pharmaceutical Ingredients/API by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 114: Rest of Europe 15-Year Perspective for Active Pharmaceutical Ingredients/API by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 115: Asia-Pacific Current & Future Analysis for Active Pharmaceutical Ingredients/API by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 116: Asia-Pacific Historic Review for Active Pharmaceutical Ingredients/API by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 117: Asia-Pacific 15-Year Perspective for Active Pharmaceutical Ingredients/API by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027
    • TABLE 118: Asia-Pacific Current & Future Analysis for Active Pharmaceutical Ingredients/API by Manufacturer - Captive and Merchant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 119: Asia-Pacific Historic Review for Active Pharmaceutical Ingredients/API by Manufacturer - Captive and Merchant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 120: Asia-Pacific 15-Year Perspective for Active Pharmaceutical Ingredients/API by Manufacturer - Percentage Breakdown of Value Sales for Captive and Merchant for the Years 2012, 2020 & 2027
    • TABLE 121: Asia-Pacific Current & Future Analysis for Active Pharmaceutical Ingredients/API by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 122: Asia-Pacific Historic Review for Active Pharmaceutical Ingredients/API by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 123: Asia-Pacific 15-Year Perspective for Active Pharmaceutical Ingredients/API by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • TABLE 124: Rest of World Current & Future Analysis for Active Pharmaceutical Ingredients/API by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 125: Rest of World Historic Review for Active Pharmaceutical Ingredients/API by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 126: Rest of World 15-Year Perspective for Active Pharmaceutical Ingredients/API by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027
    • TABLE 127: Rest of World Current & Future Analysis for Active Pharmaceutical Ingredients/API by Manufacturer - Captive and Merchant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 128: Rest of World Historic Review for Active Pharmaceutical Ingredients/API by Manufacturer - Captive and Merchant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 129: Rest of World 15-Year Perspective for Active Pharmaceutical Ingredients/API by Manufacturer - Percentage Breakdown of Value Sales for Captive and Merchant for the Years 2012, 2020 & 2027
    • TABLE 130: Rest of World Current & Future Analysis for Active Pharmaceutical Ingredients/API by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 131: Rest of World Historic Review for Active Pharmaceutical Ingredients/API by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 132: Rest of World 15-Year Perspective for Active Pharmaceutical Ingredients/API by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 46